Encore Dermatology, Inc. Announces Phase 2 Safety Data Demonstrating Lower Systemic Drug Exposure With Impoyz™ (clobetasol propionate) Cream, 0.025% Compared to Temovate® (clobetasol propionate) Cream, 0.05%